|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Trinh VA: Current management of metastatic
melanoma. Am J Health Syst Pharm. 65(Suppl 9): S3–S8. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Geller AC, Swetter SM, Brooks K, Demierre
MF and Yaroch AL: Screening, early detection and trends for
melanoma: Current status (2000–2006) and future directions. J Am
Acad Dermatol. 57:555–572. 2007. View Article : Google Scholar
|
|
5
|
Prud’homme GJ and Glinka Y: Neuropilins
are multifunctional coreceptors involved in tumor initiation,
growth, metastasis and immunity. Oncotarget. 3:921–939. 2012.
|
|
6
|
Jia H, Cheng L, Tickner M, Bagherzadeh A,
Selwood D and Zachary I: Neuropilin-1 antagonism in human carcinoma
cells inhibits migration and enhances chemosensitivity. Br J
Cancer. 102:541–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banerjee S, Sengupta K, Dhar K, et al:
Breast cancer cells secreted platelet-derived growth factor-induced
motility of vascular smooth muscle cells is mediated through
neuropilin-1. Mol Carcinog. 45:871–880. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soker S, Takashima S, Miao HQ, Neufeld G
and Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor
cells as an isoform-specific receptor for vascular endothelial
growth factor. Cell. 92:735–745. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cao Y, Wang L, Nandy D, et al:
Neuropilin-1 upholds dedifferentiation and propagation phenotypes
of renal cell carcinoma cells by activating Akt and sonic hedgehog
axes. Cancer Res. 68:8667–8672. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hong TM, Chen YL, Wu YY, et al: Targeting
neuropilin-1 as an antitumor strategy in lung cancer. Clin Cancer
Res. 13:4759–4768. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schuch G, Machluf M, Bartsch G Jr, et al:
In vivo administration of vascular endothelial growth factor (VEGF)
and its antagonist, soluble neuropilin-1, predicts a role of VEGF
in the progression of acute myeloid leukemia in vivo. Blood.
100:4622–4628. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan Q, Chanthery Y, Liang WC, et al:
Blocking neuropilin-1 function has an additive effect with
anti-VEGF to inhibit tumor growth. Cancer Cell. 11:53–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Snuderl M, Batista A, Kirkpatrick ND, et
al: Targeting placental growth factor/neuropilin-1 pathway inhibits
growth and spread of medulloblastoma. Cell. 152:1065–1076. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Straume O and Akslen LA: Increased
expression of VEGF receptors (FLT-1, KDR, NRP-1) and
thrombospondin-1 is associated with glomeruloid microvascular
proliferation, an aggressive angiogenic phenotype, in malignant
melanoma. Angiogenesis. 6:295–301. 2003. View Article : Google Scholar
|
|
15
|
Beck B, Driessens G, Goossens S, et al: A
vascular niche and a VEGF-Nrp1 loop regulate the initiation and
stemness of skin tumours. Nature. 478:399–403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ruffini F, D’Atri S and Lacal PM:
Neuropilin-1 expression promotes invasiveness of melanoma cells
through vascular endothelial growth factor receptor-2-dependent and
independent mechanisms. Int J Oncol. 43:297–306. 2013.PubMed/NCBI
|
|
17
|
Talvensaari-Mattila A, Pääkkö P and
Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is
associated with survival in breast carcinoma. Br J Cancer.
89:1270–1275. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rotte A, Martinka M and Li G: MMP2
expression is a prognostic marker for primary melanoma patients.
Cell Oncol (Dordr). 35:207–216. 2012. View Article : Google Scholar
|
|
19
|
Väisänen AH, Kallioinen M and
Turpeenniemi-Hujanen T: Comparison of the prognostic value of
matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum
Pathol. 39:377–385. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shan B, Li W, Yang SY and Li ZR: Estrogen
up regulates MMP2/9 expression in endometrial epithelial cell via
VEGF ERK1/2 pathway. Asian Pac J Trop Med. 6:826–830. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Desch A, Strozyk EA, Bauer AT, et al:
Highly invasive melanoma cells activate the vascular endothelium
via an MM-2/integrin αvβ5-induced secretion of VEGF-A. Am J Pathol.
181:693–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dai DL, Martinka M and Li G: Prognostic
significance of activated Akt expression in melanoma: A
clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin H, Wong RP, Martinka M and Li G: Loss
of SNF5 expression correlates with poor patient survival in
melanoma. Clin Cancer Res. 15:6404–6411. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Balch CM, Gershenwald JE, Soong SJ, et al:
Final version of 2009 AJCC melanoma staging and classification. J
Clin Oncol. 27:6199–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Parikh AA, Fan F, Liu WB, et al:
Neuropilin 1 in human colon cancer: Expression, regulation, and
role in induction of angiogenesis. Am J Pathol. 164:2139–2151.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizzolio S and Tamagnone L: Multifaceted
role of neuropilins in cancer. Curr Med Chem. 18:3563–3575. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bagri A, Tessier-Lavigne M and Watts RJ:
Neuropilins in tumor biology. Clin Cancer Res. 15:1860–1864. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Escudero-Esparza A, Martin TA,
Douglas-Jones A, Mansel RE and Jiang WG: PGF isoforms, PLGF-1 and
PGF-2 and the PGF receptor, neuropilin, in human breast cancer:
Prognostic significance. Oncol Rep. 23:537–544. 2010.PubMed/NCBI
|
|
29
|
Bachelder RE, Crago A, Chung J, et al:
Vascular endothelial growth factor is an autocrine survival factor
for neuropilin-expressing breast carcinoma cells. Cancer Res.
61:5736–5740. 2001.PubMed/NCBI
|
|
30
|
Whitaker GB, Limberg BJ and Rosenbaum JS:
Vascular endothelial growth factor receptor-2 and neuropilin-1 form
a receptor complex that is responsible for the differential
signaling potency of VEGF(165) and VEGF(121). J Biol Chem.
276:25520–25531. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xin Y, Li J, Wu J, et al: Pharmacokinetic
and pharmacodynamic analysis of circulating biomarkers of
anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in
patients with advanced solid tumors. Clin Cancer Res. 18:6040–6048.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hofmann UB, Westphal JR, Van Muijen GN and
Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest
Dermatol. 115:337–344. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu K, Fan J, Zhang L, et al: PI3 K/Akt to
GSK3β/β-catenin signaling cascade coordinates cell colonization for
bladder cancer bone metastasis through regulating ZEB1
transcription. Cell Signal. 24:2273–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
